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Abstract: Despite positive clinical experience and the published
clinical benefits of monotherapy with low-or medium-dose inhaled
corticosteroids or combination therapy with ICS  long-acting
beta-agonist to treat asthma, many patients remain suboptimally
controlled. Alternative approaches are needed, and 3 options that
have had some success are: 1) using the patient’s level of inflam-
mation by established biomarkers to set treatment; 2) self-manage-
ment incorporating flexible dosing; and 3) using a single inhaler for
rescue and maintenance therapy. Which strategy for which patient
depends ultimately on the individual patient’s disease burden, life-
style, comorbidities, preferences, and his or her ability to self-
manage the disease, including assessing symptoms and adhering
with therapy.
Key Words: asthma, inhaled corticosteroid, flexible dosing,
combination therapy, long-acting beta-agonist
(WAO Journal 2010; 3:31–37)
Current recommendations for managing asthma are basedon positive outcomes associated with the use of low-dose
inhaled corticosteroids (ICS) and higher dose ICS or ICS 
long acting beta-agonist (LABA) in combination as recom-
mended at steps 2 and 3, respectively, in both the GINA and
EPR-3 guidelines.1,2 However, many patients remain uncon-
trolled despite the benefits of treatment demonstrated in
clinical trials. Therefore, there is a substantial unmet need.
Within this group some patients will have severe asthma,
which may be ‘difficult-to-treat’ or ‘refractory’ to high doses
of ICS or even oral corticosteroids with or without other
medications. This group presents a clinical challenge and
needs to be managed by an asthma specialist. Control can be
regained in some using alternative strategies. Recognizing
this, the question is: “What can we do to improve asthma
control for these step 2 and step 3 patients.”
Alternative approaches are, thus, needed to improve
asthma control. Three options that have had some success
will be reviewed briefly: 1) treating patients according to their
level of inflammation as demonstrated by established biomar-
kers; 2) flexible dosing for patient self-management; and 3)
using a single inhaler.
TREATING PATIENTS ACCORDING TO THEIR
LEVEL OF INFLAMMATION
A controlled study compared patients with asthma who
were treated according to standard British Thoracic Society
guidelines and patients who were treated based on their level
of inflammation as determined by sputum eosinophil counts.3
Striking differences were reported between the 2 groups, with
more patients treated by level of inflammation showing
marked reductions in the number of severe exacerbations
(Fig. 1) and reductions in hospital admissions.3 This obser-
vation has been replicated in 2 further studies and has been
confirmed in a metaanlaysis.3–6
Sputum-based treatment is now recommended by the
British Thoracic Society.7 However, in these studies the
benefit of managing patients based on sputum was limited to
those with more severe disease and to those who showed
eosinophilia at the time of exacerbation. Patients who have
exacerbations related to neutrophilia may respond better to
different approaches to therapy, but this requires further study.
FLEXIBLE DOSING
Flexible dosing appears to be an effective alternative
for asthma management. Intermittent therapy used as needed
has been studied in patients with mild asthma. Fixed doses of
budenoside given twice-daily as monotherapy or in combi-
nation with zafirlukast were superior to intermittent, symp-
tom-guided treatment as measured by prebronchodilator
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forced expiratory volume in the first second (FEV1), exhaled
nitric oxide, sputum eosinophilia, asthma control scores, and
symptom-free days.8 However, improvements in quality of
life measurements, postbronchodilator FEV1, morning PEF,
and rates of exacerbations were similar in all treatment
groups, suggesting that intermittent therapy could be compa-
rable to fixed-dose ICS.8 In a study randomizing patients to
as-needed albuterol, as-needed beclomethasone dipropionate
(BDP), fixed daily BDP/albuterol, or as-needed BDP/albu-
terol, symptom-driven use of BDP/albuterol was as effective
as regular use of BDP, with a lower cumulative dose of ICS
over 6 months.9 A randomized trial of 3400 patients reported
that formoterol used as needed provided better protection
against severe exacerbations than terbutaline; the addition of
budenoside to the as needed formoterol enhanced the reduc-
tion in exacerbations.10
USING A SINGLE INHALER
Use of a single inhaler containing a LABA and ICS
combination appears to provide more effective asthma con-
trol at lower ICS doses,11 and for acute symptoms the com-
bination of budenoside/formoterol administered by Turbu-
haler has been shown to be well tolerated and as effective a
bronchodilator as albuterol administered by pressurized me-
tered-dose inhaler.12 A metaanalysis of 15 studies represent-
ing a total of 15,000 patients found that, with respect to
treatment failure defined by hospitalization, use of oral cor-
ticosteroids, or withdrawal from a study, patients using the
budenoside/formoterol combination in a single inhaler
showed better improvement than those using a fixed dose of
budenoside or fomoterol.13
Indeed, using budenoside/formoterol (Symbicort) as
maintenance and reliever therapy (ie, the “SMART” ap-
proach) appears to be particularly effective. In terms of
exacerbation burden and time to first severe exacerbation, the
SMART approach was favored over the use of budesonide/
formoterol plus either terbutaline or formoterol as reliever
(Fig. 2) and also over fluticasone propionate/salmeterol as
maintenance plus terbutaline as reliever.14 Data from this
study also showed that the SMART approach controlled
asthma to a similar degree as the combination maintenance
plus separate reliever regimens, but at lower overall drug
doses. The results were consistent with those from a similar
study in which physicians were able to titrate fluticasone
propionate/salmeterol to reflect real-life situations.14
It is not clear why the SMART approach is effective.
ICS may modulate airway remodeling as illustrated by de-
creased smooth muscle, reduced epithelial damage, and inhi-
bition of myofibroblast differentiation after treatment.15,16
Data from recent studies suggest that adding a LABA en-
hances these effects.17–21 Eight of 10 studies in a recent
metaanalysis favored ICS/LABA combinations over in-
creased ICS doses as a step-up for patients with mild to
moderate asthma,22 and the synergistic effects of ICS and
LABA might also occur in patients with severe asthma.23
The synergistic effects of ICS and LABA do not dis-
tinguish between patients on maintenance therapy and those
who also use the combination as a reliever. However, in a
survey of 3500 patients, patients using short-acting beta-
agonists (SABA) as a reliever adjusted their reliever medi-
cations early, when warning signs of an exacerbation
occurred, and showed a 4-fold increase in reliever treatment
at the time of worst symptoms.24 Patients using additional
ICS doses for acute symptom relief did not show this same
magnitude of increase. These data are consistent with those
from another study, which suggested that quadrupling the
ICS dose, but not doubling it, can shorten the course of an
exacerbation.25
FIGURE 1. Cumulative severe
exacerbation rate in patients
treated according to the British
Thoracic Society (BTS) asthma
management guidelines (n 
37) or by normalization of in-
duced sputum and reduction in
symptoms (n  37). A total of 7
hospital admissions were re-
ported during the 12 month
treatment period, 6 in the BTS
management group and 1 in
the sputum management group
(P  0.002).3
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In a study in which the budesonide/formoterol combi-
nation was used as maintenance and reliever therapy, super-
imposed plots of symptoms and peak expiratory flows (PEF)
on use of the combination as rescue indicated that, similar to
the SABA data described above, patients increased their use
of budenoside/formoterol before the onset of their worst
symptoms.26 The data support earlier reports that increasing
the combination dosage can prolong time to first severe
exacerbation, increase time to medical intervention, and re-
duce the overall risk of exacerbation.27,28 Thus, the data
suggest that patients using the SMART approach increase
their use of medication when they experience warning signs of
an impending exacerbation. With the combination therapy the
increased dosage of ICS may be sufficient to influence exacer-
bation frequency. An alternative, though controversial, explana-
tion is that SABA exert negative effects, as suggested by data
showing that SABA use reduces asthma control, aggravates
airway response to allergen challenge, and increases mast cell
mediator release.29,30 However, a 2007 study found no evidence
of such harm associated with SABA.31
Despite early evidence suggesting a LABA-associated
risk for sudden death or exacerbations,30 a recent study has
FIGURE 3. Proposed modified
stepwise approach for managing
asthma in patients 5 years of
age with persistent mild or
moderate disease, focus on
added step between 3 and 4
(adapted from GINA).
FIGURE 2. Time to first severe
asthma exacerbation in patients
treated with budesonide/formot-
erol (160/4.5 g bid, combina-
tion) plus as needed therapy
with terbutaline (0.4 mg, n 
1138), formoterol (4.5 g, n 
1137), or the combination
(SMART, n  1107). All patients
randomized were symptomatic
on the maintenance combina-
tion therapy during a 2-week
run-in. Reprinted from Rabe KF,
Atienza T, Magyar P, Larson P,
Jorup C, Lalloo UG. Effect of
budesonide in combination with
formoterol for reliever therapy in
asthma exacerbations: a ran-
domized controlled, double-
blind study. Lancet. 2006;368:
744–753, with permission from
Elsevier.10
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found no such evidence of when a LABA is used in combi-
nation with ICS.32 These data support the preference for a
combination of low-dose ICS and LABA at treatment step 3
in the GINA guidelines.1
It is clear that for managing the asthma patient, one size
does not fit all. Different therapeutic strategies must be
weighed against the individual patient’s disease burden, life-
style, comorbidities, and preferences. This is true regardless
of the patient’s initial level of severity, and while our focus
has been on steps 2 and 3, many of the suggestions are
applicable to managing patients at other levels. Guideline
recommendations are just that, a guide for therapeutic deci-
sion-making. Also important is the patient’s phenotype, the
ability of the person to judge changes in symptoms, and
adherence with treatment.
Most patients seem to prefer flexible dosing ap-
proaches. A study of preferences among patients with mild
asthma found that the percentage of patients preferring to use
beclomethasone and formoterol inhalers on an as needed
basis was similar to those preferring once-daily ICS/LABA in
a single inhaler; also, more patients preferred either option
than the regular use of a leukotriene receptor agonist with
albuterol rescue.30 Data from a small, open-label study across
44 primary care practices also suggested that adherence
increases with a single-inhaler approach.33 Additionally, the
costs for single-inhaler therapy are likely to be lower, because
patients use less drug overall.34
At present there is no simple means to phenotype
patients with asthma. Biomarkers are not yet sophisticated
enough and economic justification is not yet clear enough to
apply this approach to all patients with asthma. For now, it
may simply be preferable to prescribe a single-inhaler, flexible
dosing approach as a step-up between steps 3 and 4 (Fig. 3).
Patients who do not achieve asthma control on this regimen
could then be referred to difficult-asthma services and care,
with more detailed phenotypic analysis. In this scenario,
careful phenotyping would be restricted to patients with more
severe disease and greater disease burden, where the expense
could be better justified. This would be a truly patient-
centered therapeutic approach.
DISCUSSION
Dr. Oppenheimer: My question is, “How can we
really do this in our practices?” In the US, if we give our
patients permission to do this and something goes wrong, the
Food and Drug Administration (FDA) will be on the side of
the plaintiff.
Dr. Bukstein: I agree it’s a problem, but I think with
good communication and proper documentation, it can be
overcome. The key is communication with patients. I tell my
patients that this is not FDA-approved, but it is a form of
therapy that I think might be effective for them. Then I give
them a choice of therapy, and I document the conversation, that
I explained the risks and benefits to the patient and that they
made their decision based on their individual needs. There are
many things that may not be approved but are still the best
practice for that individual patient.
Dr. Brightling: I agree. What’s absolutely key with a
combination inhaler is that you can overcome the concern
about using LABA in the absence of ICS.
Dr. Kaliner: Dr. Oppenheimer, the question is a good
one and one we face every day in practice. As the asthma
experts in our communities, where is the fear of trying
something new? The fear is lawsuits or reputation. We set the
standard of care for treating asthma. The guidelines provide
general rules, but they are only guidelines; you have to add
your personal experience. I think most patients are really
thrilled when we try new things. It’s our job to lead the pack
and not to wait for someone 10 years from now to finally
recognize that this works.
Dr. Luskin: Dr. Canonica, how comfortable should we
be with formoterol and its safety, particularly when we’re
offering our patients the option to use it as rescue therapy?
Dr. Canonica: First, let me say that in southern Europe
we don’t have so many problems with the LABAs. It is
mainly a US issue.
Dr. Luskin: We heard that formoterol is an “improved
LABA” and that the presence of the ICS protects against any
potential adverse effects because of the LABA. Does the data
support that?
Dr. Bousquet: The published data suggested that ICS
may protect against the adverse events observed when LABA
were used alone. However, I don’t think this has been proven
by subsequent studies, despite the comments of the December
2008 panel at the FDA. For me, there are no real side effects
of LABA, and this debate is dangerous because if we stop
LABA, we’ll have more deaths from asthma.
Dr. Bukstein: We need to get patients to understand
that the burden of asthma therapy really is not very high. The
predominance of data did not show that LABA are harmful.
If patients are overly concerned about side effects, they are
going to make the wrong decision and won’t take the medi-
cation.
Dr. Luskin: So, for the formoterol-ICS combination
products, should we be comfortable with regular use plus
as-needed use; 1, 2, or maybe 3 doses more during a day?
Dr. Bousquet: First, remember that the problem ini-
tially was the dose of ICS used and not the dose of LABA.
Second, studies have shown that formoterol is safe at doses
up to 54 g. There are early adverse effects (eg, tremor and
tachycardia) that are probably not so important; there are also
long-term effects, including serious exacerbations, even
deaths. However, these have occurred mostly in patients
using LABA as monotherapy, not with combination therapy.
Finally, I think that we have to be very careful not to
say to patients, “This is dangerous,” because in reality deaths
due to asthma have decreased considerably, particularly with
use of combination therapy.
Dr. Brightling: We also need to think about when to
move on to the other paradigm for the individual patient. For
me, that is when the patient is not getting good control with
the flexible dosing approach. At that point you need more
intensive investigation and, maybe, more continuous treat-
ment under the management of an asthma specialist.
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Dr. Canonica: In Italy, the initial proposal was to use
the budesonide/formoterol combination bid plus prn up to 2
additional doses if needed. The concept then was to reduce
dosing, but because of the costs of the treatment and not
because of side effects. Sometimes we have to look at the
reality from different perspectives.
Dr. Spector: I’d like to ask about another type of
flexible dosing that wasn’t brought up; namely, using high
doses of ICS to treat exacerbations. At least from pediatric
studies (eg, Rodrigo et al) it seems that that’s another alter-
native for getting over an exacerbation successfully without
using a LABA.
Dr. Bukstein: But, the ICS doses suggested are high
enough to get systemic absorption, so why not just use oral
corticosteroids?
Dr. Spector: Well, it’s got the advantage that Dr.
Brightling was talking about, the patient is using the same
inhaler; and, presumably, only for a short period of time, to
get them over an episode. I’m bringing it up because I don’t
think it’s been studied very well, and maybe it should be a
study for the future.
Dr. Luskin: Does the panel agree that the mechanism
of success of SMART, assuming that SMART actually
works, is timing? That’s the theory, that we’re really intro-
ducing doses of ICS earlier than we might otherwise; and
doubling the ICS dose doesn’t seem to work. So, is this all
timing or are there other nongenomic effects?
Dr. Bukstein: Maybe it’s better adherence with once-
a-day dosing and carrying only one inhaler.
Dr. Bousquet: Most patients do what they want. We
should remember that. So with a single inhaler, the approach
becomes very simple. They use what they need. The only
warning that I give my patients is to say that if they need to
use their inhaler 4 times a day or more for longer than 3 days,
they need to contact me. This is a safety issue.
Dr. Calhoun: There are 2 LABA regulatory issues
here. One is using LABA in asthma, as in the SMART study;
the other is the use of the LABA, formoterol, in a mainte-
nance and rescue kind of SMART study. As Dr. Bousquet
said, the evidence that LABAs are harmful in asthma is
trivial. That question was asked and answered definitively at
the December 2008 FDA meeting, and unless new data arise
regarding safety, I don’t think that question will come up
again. The issue about maintenance and relief might be
different based on the framework in which the FDA operates.
Their mandate is to establish that drugs on the US market are
safe and effective. For a combination product, the individual
components must be shown to contribute to the overall
efficacy. This is not a problem for maintenance; but it is more
difficult to show improvement on the reliever side of the
equation. The reliever effect of formoterol is pretty clear. The
benefit of adding the ICS, however, is not so clear. Synergy
has not been shown clinically in terms of quick relief. Thus,
you must convince the agency that using the combination cuts
down on the need for more reliever.
However, the rigid framework of the FDA does not
necessarily need to constrain physicians who are operating at
the cutting edge. We’re not doing things that are out of the
mainstream. We’re not putting patients’ safety at risk, so as
long as the patient is aware that this is technically off-label.
I think Dr. Kaliner’s approach is correct. We ought to be
pushing the envelope just a little bit, as long as it leads to
better patient care.
Dr. Oppenheimer: It needs to be put in the framework
of higher than recommended doses in the US.
Dr. Calhoun: Yes, we need to be careful how we use the
rescue piece because formoterol is clearly where the toxicity is.
So, we need to have an upper limit of the number of puffs and
some discussion with the patient that is documented.
Dr. Luskin: Dr. Bousquet uses more than 4 times a day
for 3 days, for a phone call. How does the panel feel about that?
Dr. Bukstein: I use a similar approach: more than 4
times a day for 2 consecutive days requires a phone call to me.
Interestingly, we almost never get phone calls from patients
doing that; they tend to control their disease fairly well.
Dr. Brightling: We also have a similar approach and do
not get many phone calls from patients using single inhaler therapy.
Dr. Canonica: I agree, we have the very same experience.
Dr. Kaliner: This is a fine set of suggestions, but I would
add peak flow measurements. We tell our patients to contact the
office at a certain point of peak flow drop (eg, 40%). That’s our
other way of determining how severe their problem is.
Dr. Hargreave: I have 2 differences of opinion. First,
I don’t think that we have the evidence that doubling the dose
of ICS at the start of an exacerbation does not work. I have a
different interpretation of that study. The subjects, who had
been followed over a long period of time, were on ICS and
had an exacerbation that lasted for about 2 weeks. The
placebo and active groups were similar, which says to me that
this was a viral noneosinophilic exacerbation, which would
not be expected to respond to steroid. I don’t think we can do
these types of studies unless we also do inflammatory mea-
surements to see if the exacerbation is steroid responsive.
Dr. Luskin: This is important. We know it’s proven
that ICS are the best drugs of first choice early on; but we also
know that one size doesn’t fit all. Going back to the idea of
SMART therapy and looking at the data, there clearly is a
benefit to maintenance and reliever therapy with one combi-
nation inhaler. But, who are the responders? Who are the
candidates for this type of approach?
Dr. Bukstein: I usually present SMART therapy as an
option to someone who I think can comply with it, a patient who
can judge their own symptoms, peak flows and know when they
are having increasing problems. In other words, it is the patient
who has good insight into his or her disease who is appropriate
for this approach. A few PCPs that do this have told me that this
approach works so well that if a patient is failing, that’s a signal
for referral. It indicates more complex problems.
Dr. Luskin: So, we need to add that if this approach
doesn’t work, there should be a specialist referral.
Dr. Bousquet: I agree.
Dr. Brightling: That underscores exactly my presen-
tation. Ideally, it would be great to try to understand the
triggers before defining treatment; but at this point in time we
don’t have simple ways to do that. It is simpler to give
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treatment and then, if the patient fails, go back and try and
understand the disease, the triggers, and the phenotypes.
Dr. Luskin: Is there a clinical phenotype that helps
you determine whether or not this patient is an appropriate
candidate?
Dr. Brightling: The presence of eosinophilia is a good
predictor of response to ICS. Where we struggle are the
patients who don’t have eosinophilic inflammation because
we don’t have good therapies for them. But, if you’re going
to give combination therapy up front anyway, then you could
argue against measuring the inflammation in the beginning.
You just treat the patient.
Dr. Kaliner: So, it depends on what kind of patients
you actually see. The level 2 and 3 patients are easy to treat,
and that would be the place where this approach fits without
any problems. But I usually see patients who are level 4 and
higher. These patients first have to be stabilized at a much
greater degree of control.
Dr. Bukstein: Another problem with using the formot-
erol/ICS inhaler as a reliever is that it is new and different
approach. So, the patient who maybe goes to the pharmacist
or to another physician or to the emergency room is told,
“You shouldn’t do that. Here’s the inhaler that you should use
to move up and down.” And patients usually follow their
most recent instructions.
Dr. Luskin: Also, if a patient is on bid combination
therapy (which is a month’s worth) but uses it extra for
rescue, is there problems getting a refill?
Dr. Bukstein: Huge problems; you almost have to
supplement them with samples.
Dr. Hargreave: For the majority of doctors who have
a short time to see a patient, I have no issue with the SMART
approach. One inhaler is fine. But one of the problems I have
with guidelines is that specialists, who have more time and
have the ability to phenotype patients and to understand
what’s going on, yet don’t do these things because they
follow the guidelines. That’s wrong. For example, a lot of
people that I see just need a certain dose of ICS. Once
symptoms are controlled, they don’t need a short-acting
bronchodilator, so, why should they be given a long-acting
bronchodilator? And this isn’t a small number of patients. I
would caution against everybody using the SMART ap-
proach. I think as specialists we need to be a bit more aware
of the other approaches.
Dr. Bousquet: That would be nice if patients were
compliant. Many of the serious asthmatics I see are severe
because they don’t take their drugs.
Dr. Bukstein: I agree with Dr. Bousquet. The optimal
approach would definitely be to control somebody on a
small daily dose of ICS, but that doesn’t occur as often as
we’d like.
Dr. Kaliner: We’re really talking about a new con-
cept in asthma treatment. We were taught that using ICS
regularly would prevent remodeling and exacerbations,
and we advocated that approach despite the fact that our
patients didn’t use their medications regularly. The studies
about prn ICS and the SMART approach are opening up
new opportunities for managing our patients. Dr. Har-
greave is saying that level 2 patients don’t generally need
a combination product and shouldn’t be using one. They
should use the lowest level of ICS and then increase the
dose as needed for exacerbations. However, let’s be clear,
with the guidelines and the data about new products and
approaches such as flexible dosing, we are evolving new
paradigms. This discussion is truly important, and that is a
key purpose for this meeting.
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